<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316665</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A006336-40</org_study_id>
    <nct_id>NCT02316665</nct_id>
  </id_info>
  <brief_title>Effect of Sleep Apnea Treatment on Type 1 Diabetes</brief_title>
  <acronym>DIADEME</acronym>
  <official_title>Effect of Continuous Positive Airway Pressure Treatment on Nocturnal Glycemia of Patients Having Type 1 Diabetes and Sleep Apnea Syndrome: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société francophone de pneumologie de langue francaise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: To address the role of continuous positive airway pressure (CPAP)on nocturnal&#xD;
      glycemia in patients having type 1 diabetes and sleep apnea syndrome.&#xD;
&#xD;
      Investigators make the hypothesis that sleep apnea syndrome impacts nocturnal glycemia in&#xD;
      type 1 diabetic patients and that continuous positive airway pressure treatment will permit&#xD;
      to improve the nocturnal glycemic profile.&#xD;
&#xD;
      Study design: Adult patients with type 1 diabetes will be recruited for an extensive study of&#xD;
      sleep habits and assessment of sleep breathing disorders. When patients will present with&#xD;
      severe sleep apnea syndrome (apnea-hypopnea index above 30 events/hour) and insufficient&#xD;
      glycemic control (HbA1c &gt; 7.5%), they will be randomized in continuous positive airway&#xD;
      pressure treatment or sham-continuous positive airway pressure treatment group for three&#xD;
      months.&#xD;
&#xD;
      Main outcome: Nocturnal glycemic control will be assessed for 5 days before and after three&#xD;
      months of the allocated treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of clinical study procedures will be checked by on-site audit.&#xD;
&#xD;
      Patient self-reported past medical history will be checked by reviewing medical records.&#xD;
&#xD;
      Paper case report forms will be used.&#xD;
&#xD;
      For the baseline extensive study of sleep habits, the following data are recorded:&#xD;
&#xD;
        -  Self-reported sleep diary (7 days)&#xD;
&#xD;
        -  Actimetric device (7 days)&#xD;
&#xD;
        -  Munich Chronotype Questionnaire&#xD;
&#xD;
        -  24h-dietary recall&#xD;
&#xD;
        -  Salivary collections every 30 minutes between 7:30 pm and 22:00 pm on one night to&#xD;
           address the dim light melatonin onset.&#xD;
&#xD;
        -  Other questionnaires: Job strain questionnaire, EPICES (precarity questionnaire) and&#xD;
           DQOL (diabetes related quality of life)&#xD;
&#xD;
        -  Nocturnal oxymetry&#xD;
&#xD;
      Blood measurements: HbA1c, lipidic profile, microalbuminuria, creatinin&#xD;
&#xD;
      After baseline assessment, patients having an abnormal nocturnal oximetry will be explored by&#xD;
      polysomnography in order to detect a sleep apnea syndrome.&#xD;
&#xD;
      Investigators anticipate, based on a previous pilot study of our group (&quot;Borel&quot; Diab Med&#xD;
      2010), that 30% of screened patients will present with sleep apnea.&#xD;
&#xD;
      If patients present with severe sleep apnea (IAH &gt; 30 events/hour) and HbA1c &gt; 7.5%, they&#xD;
      will be randomized for the intervention.&#xD;
&#xD;
      Sample size: based on a previous study by &quot;Pallayova&quot; et al. in patients having type 2&#xD;
      diabetes, investigators anticipate a difference between groups of 1.3 (SD 2.07) for the mean&#xD;
      nocturnal glycemia. For a alpha threshold of 5% and a study power of 80%, the study should&#xD;
      include 32 patients in each group. Taking in account a possible 25% of dropout the study will&#xD;
      need to include 40 patients by randomized arm to demonstrate an effect.&#xD;
&#xD;
      Statistical analysis: An intention-to-treat analysis will be performed. Missing data for the&#xD;
      continuous positive airway pressure group will be replaced by the median value at three-month&#xD;
      of the sham-continuous positive airway pressure group and reciprocally.&#xD;
&#xD;
      In a second analysis, a per-protocol analysis will be performed limited to patients having&#xD;
      completed their treatment in allocated group and having an adherence to continuous positive&#xD;
      airway pressure or sham-continuous positive airway pressure treatment for more than 4-hours a&#xD;
      night.&#xD;
&#xD;
      Normality of data will be checked by Kurtosis and Skewness tests. The significance level will&#xD;
      be set at 5%.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in mean nocturnal glycemia</measure>
    <time_frame>3 months</time_frame>
    <description>Measured from continuous glycemic monitoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>24h ambulatory blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the variability of nocturnal glycemia</measure>
    <time_frame>3months</time_frame>
    <description>Measured on nighttime recording of continuous glycemic monitoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sleep duration after intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Actimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean systolic blood pressure after intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Self-monitoring blood pressure and heart rate device, at home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chang in sleep timing after intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Actimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily activity after intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Actimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean diastolic blood pressure after intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Self-monitoring blood pressure and heart rate device, at home</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean heart rate after intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Self-monitoring blood pressure and heart rate device, at home</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>continuous positive airway pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive continuous positive airway pressure during three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-continuous positive airway pressure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive sham-continuous positive airway pressure during 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous positive airway pressure</intervention_name>
    <description>continuous positive airway pressure treatment during three months with adherence recording</description>
    <arm_group_label>continuous positive airway pressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham-continuous positive airway pressure</intervention_name>
    <description>Sham-continuous positive airway pressure during three months with adherence recording</description>
    <arm_group_label>Sham-continuous positive airway pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with type 1 diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patient with acute metabolic disorders during the past three months&#xD;
&#xD;
          -  Shift workers&#xD;
&#xD;
          -  Institutionalized patient&#xD;
&#xD;
          -  Enteral and parenteral nutrition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Pépin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HP2 INSERM U1042 laboratory, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grenoble University hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Sleep apnea syndrome</keyword>
  <keyword>Nocturnal glycemia</keyword>
  <keyword>Continuous glucose monitoring system</keyword>
  <keyword>Continuous positive airway pressure</keyword>
  <keyword>Sleep habits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

